Lupin Limited (500257) Fair Value & Analysis
Other · IN · Market cap ₹946B
Fair value as of: Jul 4, 2026
From 24 valuation models · updated today
Share price +9.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,852 – ₹2,476 · fair‑value band ₹1,779 – ₹4,113 · the ₹2,476 price screens above the ₹2,372 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lupin Limited (500257) currently trades at ₹2,476, while our model-based Fair Value estimate is ₹2,372 — implying the stock looks roughly 4.2% overvalued today. We read business quality at 73/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Net debt stands at ₹17.4B. The stock trades on a trailing P/E of 28.3. Fundamentals as of Jul 4, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) worldwide. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system (CNS), gastro-intestinal, anti-infectives, nonsteroidal anti inflammatory drug therapy, anti-TB, and cephalosporins. The company also develops drug delivery technologies; and offers biosimilars for various therapies, such as oncology, anti-inflammatory, anti-virals, rheumatoid arthritis, endocrinology, diabetes, ophthalmology, and women?s health. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain, and metabolic disorders. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Lupin Limited reported revenue of ₹275B in FY2025 versus ₹164B in FY2021, a compound +13.8%/yr. Reported net income was ₹53.3B in FY2025.
Is 500257 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 500790 500790 | ₹1,459 | ₹279.60 | -81% |
| GRFP GRFP | €6.43 | €2.58 | -60% |
| Stifel Financial Corporation SFB | $19.76 | $68.51 | +247% |
Explore undervalued stocks
Frequently asked questions
Is Lupin Limited (500257) undervalued?
What is the fair value of 500257?
What is the quality score of 500257?
What is the net profit margin of 500257?
Does Lupin Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.